OraSure Technologies Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OraSure Technologies, Inc. on December 22, 2004. The filing serves as a Regulation FD disclosure regarding a significant contract award and an update to the company's financial outlook.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current or prior periods. The only specific financial value disclosed is a new contract value of approximately $2.3 million.
Material Changes and Events
- New Contract: The Centers for Disease Control and Prevention (CDC) agreed to purchase approximately $2.3 million worth of OraSure's OraQuick ADVANCE Rapid HIV-1/2 Antibody Tests.
- Guidance Update: The company issued an update to its financial guidance for the 2005 fiscal year, though specific numerical targets are not detailed in this filing text.
Outlook, Risks, and Management Commentary
Management highlighted the CDC contract as a material development. The filing incorporates a press release by reference which contains the updated 2005 financial guidance. No specific risks, contingencies, or unusual items are detailed within the text of this 8-K form itself.
Investor Verification Checklist
- Verify the specific terms and delivery schedule of the $2.3 million CDC contract in the attached press release (Exhibit 99).
- Review the detailed 2005 financial guidance numbers provided in the press release, as they are not listed in the 8-K summary text.
- Assess the impact of the CDC order on the company's projected revenue mix for 2005.